NeoClone's Management Team
Deven McGlenn - Chief Executive Officer
Deven McGlenn is CEO of NeoClone and has been involved with the company since inception in 1999 and full-time since April 2002. During his tenure he has grown the business to $7M+ in revenues, 15+ FTEs and raised over $2.5M in equity. Prior to NeoClone, he was a management consultant for Arthur Andersen where he helped Fortune 500 companies develop a strategic view of their risk profiles. Before Andersen, he was the founder and CEO of an environmental remediation firm headquartered in the Midwest. Deven has a BS in Political Science with a minor in Business Administration from Marquette University. Contact
Rachel H. Kravitz, PhD - Director of Research
Dr. Kravitz has over 18 years of experience in molecular biology, virology and immunology. She received her B.S. in Biology from Tufts University in 1989 and a PhD in Microbiology from University of California, Davis in 1998. Dr. Kravitz spent the majority of her career developing animal models to study viral pathogenesis in human diseases. Dr. Kravitz joined NeoClone in 2003, developing an active research program using ABL-MYC technology for developing diagnostic and therapeutic antibodies. The research program has garnered a successful track record of procuring both NIH-funded contracts and grants to further NeoClone’s research efforts. Contact
Uwe R. Müller, PhD - Chief Scientific Officer
Prior to joining Neoclone, Dr. Müller was VP for Applied Science at Nanosphere (Northbrook, IL), where he led the research and early development of genomic microarray-based SNP assays, as well as nanoparticle-based high-sensitivity assays for protein detection. Before joining Nanosphere, Dr. Müller held the position of Technology Director at Corning, Inc., where he developed and led the Biochemistry Research Department with responsibility for the company's global research activities in the Life Sciences. Prior to joining Corning, Dr. Müller was Director of Advanced Technology at Vysis, Inc. (now Abbott), where his research activities focused on DNA based diagnostics, including DNA probes for fluorescent in situ hybridization and the development of array based assay systems for genomic and expression analysis.
Dr. Müller received his B.S. degree in Biology from Justus-Liebig Universität, Germany, and his MS and PhD degrees in Microbiology from Kansas State University, Manhattan, KS. After a postdoc in Biochemistry (University of Wisconsin, Madison) he became an Assistant and then tenured Associate Professor in the Department of Microbiology and Immunology at East Carolina University School of Medicine (Greenville, NC).
Mark Sullivan, PhD - Director of Phage Technologies
Dr. Sullivan is the Director of Phage Technologies at NeoClone. He has years of experience manipulating immunoglobulin molecules to develop novel reagents using phage antibody technology. Dr. Sullivan is an expert in the creation of scFv libraries using novel strategies that eliminate common problems associated with production and use of complex Ab libraries. Mark has worked at the University of Rochester, Johnson & Johnson and Eastman Kodak. He received his PhD from the University of Wisconsin-Madison and his BS from Purdue University. For questions relating to antibody phage display, please contact
Ed Dunphy - Director of Marketing
As the Director of Marketing for NeoClone, Ed has been developing the company’s marketing strategies, including social media, website SEO, and public relations efforts. Ed came to NeoClone in 2007 as a seasoned research professional with over 25 years of diversified laboratory experience in immunology, cancer biology, gene therapy and molecular biology. He has since broadened his knowledge of the biotechnology and antibody industries and is overseeing the growth of NeoClone’s catalog antibody business. A graduate of the University of Chicago, Ed is also a published writer and creator of the popular science humor comic, “Lab Bratz”. Contact